The Christie sees promise in HMBD-001 for bladder cancer
Early signals from an ongoing study at The Christie Hospital in Manchester shore up the evidence for an investigational treatment …
Early signals from an ongoing study at The Christie Hospital in Manchester shore up the evidence for an investigational treatment …
Investigators at Mass General Brigham in Massachusetts, US, have reported outcomes from a study of a new immunotherapy for skin …
On 30 December 2024, Novartis reported that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) reached its primary endpoint …
Australian immuno-oncology company Imugene has dosed the first Australian subject in a Phase Ib trial of its allogeneic CAR T-cell …
Chinese biotechnology company Hanx Biopharmaceuticals has dosed the first subject in the Phase I trial of HX044, a bispecific antibody …
Taiwanese pharmaceutical company Xgene Pharmaceutical announced that its non-opioid analgesic drug XG005 has reduced acute pain in patients after surgery …
Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity …
The University of Birmingham has launched the global ‘Glo-BNHL’ clinical trial assessing new therapies to treat paediatric patients with B-cell …
According to GlobalData’s Clinical Trials Database, non-industry sponsored trials lead rare disease indications, accounting for 55.6% of all trials since …
Cocrystal Pharma has announced its intent to extend enrolment for its Phase IIa human challenge trial of the oral influenza …
Israeli Medical Cannabis Agency (IMCA) at the Ministry of Health has renewed SciSparc’s clinical trial of SCI-210 aimed at treating …
Novartis has reported positive topline outcomes from the Phase III STEER trial of an investigational gene therapy, intrathecal onasemnogene abeparvovec …
Sensorion has completed subject enrolment in the first cohort of Phase I/II Audiogene trial of gene therapy injection, SENS-501 for …
China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has approved Alphamab Oncology’s investigational new drug application (IND) …
Ractigen Therapeutics has dosed the first subject in the randomised Phase I clinical trial of its small interfering RNA (siRNA) …